INVESTOR RELATIONS
Amato and Partners
90 Park Avenue, 17th Floor
New York, NY 10016
admin@amatoandpartners.com
ANALYST COVERAGE
ROTH Capital Partners
(646) 358-1907
Joseph Pantginis, PhD: jpantginis@roth.comInitiation Report: ROTH Initiates Research Coverage on DelMar
Latest Coverage: ROTH Update on DelMar Pharmaceuticals (February 18, 2015)
Maxim Group LLC
(212) 895-3604
Jason Kolbert: jkolbert@maximgrp.comInitiation Report: Maxim Initiates Research Coverage on DelMar
Latest Coverage: Maxim Update on DelMar Pharmaceuticals (February 18, 2015)
SeeThru Equity, LLC
(646) 495-0939
Ajay Tandon: ajay@seethruequity.comInitiation Report: SeeThru Equity Initiating Coverage
Latest Coverage: SeeThru Equity Update Report on DelMar Pharmaceuticals, Inc. (May 12, 2015, OTCQX: DMPI, Target Price: $4.53)
LifeSci Advisors, LLC
(646) 597-6987
Andrew McDonald: amcdonald@lifesciadvisors.comInitiation Report: LifeSci Advisors Initiates Research Coverage on DelMar
Latest Coverage: Company Update: DelMar Completes Dose Escalation of Phase I/II in GBM and Preps for Registration Trial (April 21, 2015)
Zacks Small-cap Research
(312) 265-9466
Grant Zeng, CFA: gzeng@zacks.comInitiation Report: Zacks Initiates Research Coverage on DelMar
Latest Coverage: DMPI: Encouraging preliminary efficacy data reported at ASCO, Ready to advance VAL- 083 to pivotal Phase II/III trial in 2H2015, pipeline will be expanded to include NSCLC – Buy (June 2, 2015)
Links to the analyst reports listed above are provided as a service to those interested in this information. We do not endorse these reports and can make no guarantee as to their accuracy or completeness. Users of these reports or visitors the analysts’ websites do so at their own risk. Those interested in investing in our company are directed to the materials filed by us with the SEC, including risk factors and risks related to forward looking statements.